Physician
Oregon Health & Science University
Oregon Health & Science University was paid $70.79M by Medicaid between Jan 2018 and Dec 2024, across 413 billing codes. Its largest line is G0463, Hospital outpatient clinic visit for assessment and management of a patient — 50% of everything it billed.
33Billing provider infoOREGON HEALTH & SCIENCE UNIVERSITY
PORTLAND, OR 97239
PORTLAND, OR 97239
33aNPI1609824010assigned 05/05/2006
33bProvider typeGeneral Practice Physician
28Total paid$70.79M
24GClaims1,421,542
24DCodes billed413
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Practice Physician providers in Oregon
Rank by total paid#1 of 23
Median peer was paid$112K
This provider vs. median634×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 208,549 | $9.26M | |
| 2019 | 197,912 | $9.46M | |
| 2020 | 151,014 | $7.35M | |
| 2021 | 225,957 | $10.20M | |
| 2022 | 203,700 | $9.71M | |
| 2023 | 228,885 | $12.59M | |
| 2024incomplete | 205,525 | $12.21M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 50% | 443,687 | 396,649 | $35.69M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 12% | 20,113 | 18,695 | $8.84M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 5.7% | 15,137 | 13,818 | $4.01M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 5.1% | 21,464 | 20,110 | $3.59M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 4.5% | 54,963 | 49,203 | $3.19M |
| 92014 | Ophthalmological services: medical examination and evaluation, comprehensive, established patient | 1.9% | 16,000 | 15,412 | $1.38M |
| 67028 | Intravitreal injection of a pharmacologic agent | 1.1% | 4,082 | 3,495 | $769K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 1.1% | 5,394 | 3,330 | $745K |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 443 | 359 | $647K |
| 92587 | <1% | 3,414 | 3,215 | $590K | |
| 0001A | <1% | 17,808 | 16,426 | $546K | |
| 92012 | Ophthalmological services: medical examination and evaluation, intermediate, established patient | <1% | 7,582 | 6,998 | $541K |
401 more codes
| 0002A | <1% | 16,287 | $522K | |
| 92004 | Ophthalmological services: medical examination and evaluation, comprehensive, new patient | <1% | 5,913 | $519K |
| 93303 | Transthoracic echocardiography for congenital cardiac anomalies, follow-up or limited study | <1% | 1,291 | $487K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 4,404 | $462K |
| 76770 | <1% | 4,470 | $449K | |
| 17380 | <1% | 1,352 | $409K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 5,194 | $376K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 1,113 | $341K |
| 77386 | <1% | 782 | $301K | |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | <1% | 88 | $291K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 6,719 | $248K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 2,164 | $217K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 478 | $195K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 750 | $192K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 1,409 | $186K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 964 | $174K |
| 80053 | Comprehensive metabolic panel | <1% | 94,435 | $166K |
| 93325 | <1% | 2,514 | $166K | |
| 92060 | <1% | 13,765 | $151K | |
| 31231 | <1% | 1,093 | $138K | |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 174 | $114K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 1,945 | $107K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | <1% | 2,005 | $102K |
| 90686 | <1% | 6,242 | $98K | |
| J0585 | Injection, onabotulinumtoxina, 1 unit | <1% | 233 | $91K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 1,153 | $89K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 113,631 | $88K |
| 0012A | <1% | 5,444 | $86K | |
| 96415 | <1% | 496 | $81K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 490 | $80K |
| Q5103 | Injection, infliximab-dyyb, biosimilar, (inflectra), 10 mg | <1% | 96 | $78K |
| J1750 | Injection, iron dextran, 50 mg | <1% | 356 | $78K |
| 93798 | <1% | 1,191 | $78K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 21,180 | $76K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 4,016 | $75K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 4,589 | $71K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 416 | $70K |
| 0004A | <1% | 2,160 | $70K | |
| 17111 | <1% | 520 | $67K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 3,027 | $63K |
| 31579 | <1% | 250 | $62K | |
| 17999 | <1% | 714 | $60K | |
| 92567 | <1% | 8,469 | $57K | |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | <1% | 899 | $51K |
| 97803 | <1% | 1,805 | $49K | |
| 76512 | <1% | 546 | $49K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 6,482 | $49K |
| 92250 | <1% | 3,287 | $49K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 96,175 | $47K |
| 92134 | <1% | 11,886 | $46K | |
| 98941 | Chiropractic manipulative treatment; spinal, 3-4 regions | <1% | 2,739 | $45K |
| G0378 | Hospital observation service, per hour | <1% | 761 | $45K |
| 59025 | Fetal non-stress test | <1% | 321 | $43K |
| 0071A | <1% | 1,131 | $41K | |
| 91200 | <1% | 524 | $41K | |
| 87536 | <1% | 1,770 | $39K | |
| 92523 | <1% | 328 | $38K | |
| 86900 | <1% | 3,599 | $38K | |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 546 | $38K |
| 0072A | <1% | 989 | $37K | |
| 96112 | <1% | 113 | $36K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 439 | $36K |
| 11100 | <1% | 188 | $36K | |
| 96900 | <1% | 1,785 | $33K | |
| 93296 | <1% | 1,569 | $32K | |
| 92557 | <1% | 1,093 | $31K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 7,798 | $31K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 1,191 | $30K |
| 90674 | <1% | 2,427 | $30K | |
| 17311 | <1% | 177 | $29K | |
| 90656 | <1% | 748 | $28K | |
| 97162 | <1% | 547 | $28K | |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 464 | $28K |
| 52000 | <1% | 57 | $27K | |
| 80061 | Lipid panel | <1% | 3,864 | $27K |
| 90870 | <1% | 64 | $26K | |
| 0011A | <1% | 1,203 | $25K | |
| 51784 | <1% | 258 | $25K | |
| 0054A | <1% | 761 | $24K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 4,081 | $23K |
| 11043 | <1% | 108 | $22K | |
| 29581 | <1% | 640 | $22K | |
| 92083 | <1% | 2,213 | $22K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 277 | $22K |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 336 | $21K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 1,045 | $21K |
| 76825 | <1% | 235 | $20K | |
| G0008 | Administration of influenza virus vaccine | <1% | 932 | $19K |
| 73610 | <1% | 821 | $19K | |
| 82728 | <1% | 6,371 | $19K | |
| J0178 | Injection, aflibercept, 1 mg | <1% | 27 | $18K |
| 76820 | <1% | 417 | $17K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 26 | $17K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 554 | $17K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 554 | $17K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 1,422 | $15K |
| 73630 | <1% | 863 | $15K | |
| 98940 | <1% | 1,048 | $15K | |
| 86833 | <1% | 491 | $15K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 3,968 | $15K |
| 86832 | <1% | 488 | $15K | |
| 36430 | <1% | 95 | $14K | |
| 97166 | <1% | 287 | $14K | |
| 92610 | <1% | 308 | $14K | |
| 94010 | <1% | 781 | $13K | |
| 64615 | <1% | 87 | $13K | |
| L4361 | Walking boot, pneumatic and/or vacuum, with or without joints, with or without interface material, prefabricated, off-the-shelf | <1% | 52 | $13K |
| 0031A | <1% | 590 | $13K | |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 260 | $13K |
| 95115 | <1% | 358 | $13K | |
| 83735 | <1% | 9,381 | $12K | |
| 97802 | <1% | 246 | $11K | |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 150 | $11K |
| 84403 | <1% | 1,289 | $11K | |
| J0475 | Injection, baclofen, 10 mg | <1% | 30 | $10K |
| 92002 | <1% | 165 | $10K | |
| 85027 | <1% | 7,339 | $10K | |
| C9257 | Injection, bevacizumab, 0.25 mg | <1% | 1,275 | $10K |
| 99442 | <1% | 466 | $9K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 8,059 | $9K |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 68 | $9K |
| 91321 | <1% | 68 | $9K | |
| 76821 | <1% | 290 | $9K | |
| 20610 | <1% | 47 | $9K | |
| 90791 | Psychiatric diagnostic evaluation | <1% | 250 | $9K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 94 | $8K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 195 | $8K |
| 96409 | <1% | 56 | $8K | |
| 86361 | <1% | 1,218 | $8K | |
| 11102 | <1% | 58 | $8K | |
| 80197 | <1% | 2,743 | $8K | |
| 82670 | <1% | 923 | $8K | |
| 98942 | <1% | 463 | $7K | |
| 92582 | <1% | 611 | $7K | |
| 76827 | <1% | 236 | $7K | |
| 71045 | Radiologic examination, chest; single view | <1% | 405 | $7K |
| 84439 | <1% | 3,654 | $7K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 239 | $7K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 5,363 | $7K |
| 0003A | <1% | 225 | $6K | |
| 92133 | <1% | 1,997 | $6K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 501 | $6K |
| 84100 | <1% | 8,047 | $6K | |
| 51741 | <1% | 689 | $6K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 120 | $6K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 932 | $6K |
| 93793 | <1% | 1,139 | $6K | |
| 31575 | <1% | 51 | $6K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,780 | $6K |
| 95004 | Percutaneous tests with allergenic extracts, immediate type reaction | <1% | 13 | $5K |
| 73130 | <1% | 255 | $5K | |
| 94761 | <1% | 42,554 | $5K | |
| 95117 | <1% | 166 | $5K | |
| 85610 | <1% | 9,003 | $5K | |
| 74018 | <1% | 1,439 | $5K | |
| 82784 | <1% | 819 | $5K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 124 | $5K |
| 43235 | <1% | 13 | $5K | |
| 77336 | <1% | 54 | $4K | |
| 76536 | <1% | 223 | $4K | |
| 90670 | <1% | 276 | $4K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 17 | $4K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 14 | $4K |
| 0111A | <1% | 123 | $4K | |
| 86850 | <1% | 3,479 | $4K | |
| Q3014 | Telehealth originating site facility fee | <1% | 746 | $4K |
| 97167 | <1% | 74 | $4K | |
| 0112A | <1% | 108 | $4K | |
| 91320 | <1% | 26 | $4K | |
| 96130 | <1% | 70 | $4K | |
| 96101 | <1% | 51 | $4K | |
| 87799 | <1% | 486 | $4K | |
| 87522 | Neg quan hep c or qual rna | <1% | 281 | $4K |
| 20611 | <1% | 15 | $3K | |
| 96113 | <1% | 34 | $3K | |
| 90685 | <1% | 154 | $3K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 238 | $3K |
| 83615 | <1% | 3,340 | $3K | |
| 86140 | <1% | 2,377 | $3K | |
| 92526 | <1% | 53 | $3K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 241 | $3K |
| 81370 | <1% | 12 | $3K | |
| 92604 | <1% | 48 | $3K | |
| 81001 | <1% | 5,115 | $3K | |
| 84484 | <1% | 2,768 | $3K | |
| 82248 | <1% | 1,373 | $3K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 143 | $3K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 65 | $3K |
| 88342 | <1% | 517 | $3K | |
| 93320 | <1% | 1,264 | $3K | |
| 71250 | <1% | 43 | $2K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 2,870 | $2K |
| 62370 | <1% | 30 | $2K | |
| 86803 | <1% | 371 | $2K | |
| 96131 | <1% | 39 | $2K | |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 2,188 | $2K |
| 86923 | <1% | 149 | $2K | |
| 92579 | <1% | 129 | $2K | |
| 72100 | <1% | 279 | $2K | |
| 84550 | <1% | 1,903 | $2K | |
| 83970 | <1% | 500 | $2K | |
| 0052A | <1% | 56 | $2K | |
| 87070 | <1% | 1,737 | $2K | |
| 83540 | <1% | 1,807 | $2K | |
| 92553 | <1% | 43 | $2K | |
| 90480 | <1% | 62 | $2K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 9,872 | $2K |
| 86901 | <1% | 3,570 | $2K | |
| 86592 | <1% | 587 | $2K | |
| 73110 | <1% | 97 | $2K | |
| 90698 | <1% | 251 | $2K | |
| 0051A | <1% | 46 | $2K | |
| 17000 | <1% | 45 | $2K | |
| 83605 | <1% | 476 | $1K | |
| 73030 | <1% | 69 | $1K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 9,276 | $1K |
| 96150 | <1% | 12 | $1K | |
| 92522 | <1% | 17 | $1K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 28 | $1K |
| 98967 | <1% | 315 | $1K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 2,256 | $1K |
| J2704 | Injection, propofol, 10 mg | <1% | 15,407 | $1K |
| 71271 | <1% | 29 | $1K | |
| 84466 | <1% | 776 | $1K | |
| 93288 | <1% | 39 | $1K | |
| 74230 | <1% | 14 | $1K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 10,407 | $1K |
| 84146 | <1% | 308 | $1K | |
| 73590 | <1% | 76 | $1K | |
| 83880 | <1% | 230 | $1K | |
| 80069 | <1% | 468 | $1K | |
| 77073 | <1% | 310 | $1K | |
| 36591 | <1% | 106 | $1K | |
| 77080 | <1% | 34 | $1K | |
| 0124A | <1% | 26 | $987.92 | |
| 82105 | <1% | 426 | $982.66 | |
| 83550 | <1% | 788 | $976.99 | |
| 92504 | <1% | 2,601 | $959.12 | |
| 82570 | <1% | 1,042 | $948.50 | |
| 92235 | <1% | 13 | $923.55 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 4,790 | $922.44 |
| 85652 | <1% | 2,234 | $916.39 | |
| 96367 | <1% | 40 | $909.67 | |
| 87077 | <1% | 1,191 | $900.60 | |
| 88185 | <1% | 34 | $888.78 | |
| 81513 | <1% | 28 | $887.60 | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 13 | $856.50 |
| 72083 | <1% | 12 | $834.89 | |
| 87634 | <1% | 133 | $831.69 | |
| 83690 | <1% | 1,631 | $781.79 | |
| 90680 | <1% | 104 | $772.94 | |
| 96402 | <1% | 27 | $760.36 | |
| 85730 | <1% | 1,054 | $718.22 | |
| 96111 | <1% | 28 | $716.73 | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 87 | $709.70 |
| 81003 | <1% | 6,918 | $699.39 | |
| 0064A | <1% | 29 | $682.98 | |
| 83521 | <1% | 219 | $671.39 | |
| 69210 | <1% | 340 | $646.96 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,471 | $624.44 |
| 92524 | <1% | 12 | $613.02 | |
| 96411 | <1% | 19 | $609.62 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 2,422 | $597.80 |
| 98943 | <1% | 49 | $588.95 | |
| 90677 | <1% | 68 | $588.26 | |
| 80076 | <1% | 265 | $583.91 | |
| 87186 | <1% | 990 | $569.34 | |
| 87497 | <1% | 109 | $561.80 | |
| 98968 | <1% | 45 | $547.95 | |
| 74455 | <1% | 12 | $519.89 | |
| 90651 | <1% | 24 | $514.96 | |
| 87517 | <1% | 27 | $510.31 | |
| 84703 | <1% | 921 | $508.06 | |
| 88184 | <1% | 37 | $449.35 | |
| 81376 | <1% | 12 | $445.82 | |
| 73560 | <1% | 55 | $445.17 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 4,257 | $417.68 |
| C1769 | Guide wire | <1% | 1,167 | $416.64 |
| 94760 | <1% | 4,974 | $414.09 | |
| 82565 | <1% | 664 | $395.95 | |
| 73502 | <1% | 25 | $395.35 | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 28 | $395.08 |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 12 | $395.00 |
| 51798 | <1% | 338 | $394.23 | |
| 84432 | <1% | 163 | $389.04 | |
| 87481 | <1% | 28 | $370.97 | |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 15 | $362.03 |
| 72082 | <1% | 84 | $359.25 | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 13 | $357.45 |
| 87081 | <1% | 79 | $354.85 | |
| 86800 | <1% | 173 | $347.68 | |
| 92025 | <1% | 52 | $342.69 | |
| 36592 | <1% | 178 | $342.52 | |
| 72110 | <1% | 72 | $330.03 | |
| 92552 | <1% | 15 | $317.92 | |
| 86780 | <1% | 26 | $307.11 | |
| 83921 | <1% | 209 | $305.42 | |
| 82024 | <1% | 67 | $280.65 | |
| 92611 | <1% | 15 | $274.56 | |
| 84156 | <1% | 450 | $259.41 | |
| 72170 | <1% | 27 | $257.59 | |
| 90744 | <1% | 12 | $251.44 | |
| 11721 | <1% | 33 | $251.05 | |
| 90723 | <1% | 28 | $237.06 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 3,181 | $229.00 |
| 82607 | <1% | 315 | $225.87 | |
| 84425 | <1% | 219 | $222.29 | |
| 83090 | <1% | 205 | $222.16 | |
| 93282 | <1% | 15 | $213.95 | |
| 87340 | <1% | 196 | $213.11 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,601 | $210.19 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 1,332 | $205.50 |
| 86480 | <1% | 57 | $199.71 | |
| 82533 | <1% | 92 | $188.21 | |
| 86334 | <1% | 131 | $146.99 | |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 8,574 | $143.49 |
| 92285 | <1% | 171 | $141.34 | |
| 73564 | <1% | 56 | $138.33 | |
| 82803 | <1% | 193 | $132.06 | |
| 86003 | <1% | 13 | $115.36 | |
| 87205 | <1% | 178 | $107.36 | |
| 86704 | <1% | 92 | $106.10 | |
| 83516 | <1% | 142 | $102.36 | |
| 80305 | <1% | 487 | $102.23 | |
| 86706 | <1% | 88 | $97.60 | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 150 | $96.26 |
| J3490 | Unclassified drugs | <1% | 283 | $95.56 |
| 72050 | <1% | 26 | $91.44 | |
| 88341 | <1% | 59 | $79.77 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 105 | $66.10 |
| 93356 | <1% | 66 | $65.36 | |
| 84702 | <1% | 39 | $55.52 | |
| 84165 | <1% | 143 | $53.48 | |
| 84305 | <1% | 116 | $49.89 | |
| 83883 | <1% | 15 | $44.33 | |
| 84132 | <1% | 15 | $43.18 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 84 | $40.38 |
| 84630 | <1% | 53 | $39.46 | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 2,171 | $35.95 |
| 87040 | <1% | 66 | $33.92 | |
| 86364 | <1% | 14 | $31.17 | |
| 81015 | <1% | 42 | $29.23 | |
| 85384 | <1% | 86 | $28.76 | |
| 82977 | <1% | 29 | $26.62 | |
| 84134 | <1% | 43 | $20.62 | |
| 84590 | <1% | 38 | $17.90 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 31 | $17.68 |
| 36416 | <1% | 5,334 | $15.24 | |
| 82378 | <1% | 34 | $15.17 | |
| 84446 | <1% | 25 | $11.00 | |
| 82525 | <1% | 25 | $9.00 | |
| 82043 | <1% | 13 | $8.76 | |
| 82550 | <1% | 15 | $7.68 | |
| 86645 | <1% | 15 | $2.81 | |
| 86644 | <1% | 15 | $2.40 | |
| 86762 | <1% | 13 | $2.40 | |
| 86708 | <1% | 41 | $2.06 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 164 | $2.02 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 106 | $0.40 |
| 91311 | <1% | 178 | $0.17 | |
| J1756 | Injection, iron sucrose, 1 mg | 0% | 74 | $0.00 |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | 0% | 101 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 132 | $0.00 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 329 | $0.00 |
| 90611 | 0% | 44 | $0.00 | |
| 92555 | 0% | 66 | $0.00 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 0% | 107 | $0.00 |
| L8613 | Ossicula implant | 0% | 99 | $0.00 |
| J3370 | Injection, vancomycin hcl, 500 mg | 0% | 29 | $0.00 |
| 96136 | 0% | 68 | $0.00 | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 133 | $0.00 |
| 87660 | 0% | 12 | $0.00 | |
| J3260 | Injection, tobramycin sulfate, up to 80 mg | 0% | 30 | $0.00 |
| 87641 | 0% | 43 | $0.00 | |
| J9370 | Vincristine sulfate, 1 mg | 0% | 30 | $0.00 |
| J1644 | Injection, heparin sodium, per 1000 units | 0% | 21 | $0.00 |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | 0% | 27 | $0.00 |
| J9190 | Injection, fluorouracil, 500 mg | 0% | 44 | $0.00 |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 14 | $0.00 |
| A4306 | Disposable drug delivery system, flow rate of less than 50 ml per hour | 0% | 13 | $0.00 |
| 96137 | 0% | 14 | $0.00 | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 73 | $0.00 |
| 11045 | 0% | 21 | $0.00 | |
| 95886 | 0% | 215 | $0.00 | |
| 51736 | 0% | 17 | $0.00 | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | 0% | 57 | $0.00 |
| A9573 | Injection, gadopiclenol, 1 ml | 0% | 41 | $0.00 |
| 87640 | 0% | 42 | $0.00 | |
| 87480 | 0% | 12 | $0.00 | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | 0% | 108 | $0.00 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 109 | $0.00 |
| 51600 | 0% | 12 | $0.00 | |
| J1597 | Injection, glycopyrrolate (glyrx-pf), 0.1 mg | 0% | 14 | $0.00 |
| 80047 | 0% | 25 | $0.00 | |
| J7999 | Compounded drug, not otherwise classified | 0% | 28 | $0.00 |
| 90647 | 0% | 13 | $0.00 | |
| 96376 | 0% | 14 | $0.00 | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | 0% | 28 | $0.00 |
| 87510 | 0% | 12 | $0.00 | |
| 76377 | 0% | 15 | $0.00 | |
| 82657 | 0% | 18 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialDOLL, JENNIFER (SR VICE PRESIDENT/CFO)
| Provider | Location | Paid |
|---|---|---|
| Regents of the University of California | Sacramento, CA | $315K |
| Oregon Health & Science University | Portland, OR | $387.48 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.